Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,661 public trials 325 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Active, Not Recruiting

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

NCT05527340

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital General Universitario Gregorio Marañón Madrid, Spain
  • Hospital Universitario 12 de Octubre Madrid, Spain
  • Hospital Son Llatzer Palma de Mallorca, Spain
  • Clínica Universidad de Navarra Pamplona, Spain
View Trial Details
Active, Not Recruiting

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Colorado Aurora, Colorado, United States
  • Mayo Clinic-Jacksonville Jacksonville, Florida, United States
  • University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 27 locations
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

NCT07084896

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • 238995 Atlanta, Georgia, United States
  • 240593 Boston, Massachusetts, United States
  • 251164 Grand Rapids, Michigan, United States
  • 239015 Madison, Wisconsin, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Indianapolis, Indiana, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
View all 38 locations
View Trial Details
Active, Not Recruiting

PRospective Multiple Myeloma Impact Study

NCT02911571

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • New York Presbyterian Brooklyn Methodist Hospital Brooklyn, New York, United States
View Trial Details
Active, Not Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Goodyear, Arizona, United States
  • University of California San Diego San Diego, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Emory University Atlanta, Georgia, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT06868667

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Aomori, Japan
  • GSK Investigational Site Fukuoka, Japan
  • GSK Investigational Site Himeji, Japan
  • GSK Investigational Site Kamakura, Japan
View all 16 locations
View Trial Details

Related conditions